BIIB Biogen
MS cliff is mostly absorbed; Biogen is fairly-to-richly priced unless Alzheimer's launches truly scale.
The story
Biogen is a roughly $10B neuroscience incumbent in a managed transition. Its multiple sclerosis franchise (Tecfidera, Tysabri) is eroding to generics and biosimilars, while launches (Leqembi, Skyclarys, Zurzuvae) and the HI-Bio and Reata pipelines are now offsetting that decline. TTM revenue has turned slightly upward. The 7% GAAP margin reflects one-off acquired IPR&D and amortization charges, not the steady-state economics of a mature specialty-pharma franchise. It is a late-mature company trying to restart modest growth, with real but not franchise-grade moats in rare neurology and Alzheimer's.
Three things changed. Revenue has inflected (10.30B TTM vs 9.68B two years ago). The margin trough comes from acquired-IPR&D charges rather than structural decline. My prior $78.51 value was 65% below a well-covered price, so it failed the market reconciliation check. I therefore raise the target margin from 19% to 25%, toward normalized ex-IPR&D pharma economics but still well below the 37.7% peak. I also raise sales-to-capital from 0.4 to 0.7, because the reported capital base is inflated by acquisition goodwill while incremental launch revenue needs little new capital. Growth stays low and the horizon stays at 7 years because MS erosion caps upside.
Value drivers
| Revenue growth (Y1) | 3.0% |
| Terminal growth | 1.0% |
| Forecast horizon | 7y |
| Target operating margin | 25.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.70 |
| Beta | 1.00 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 9.0% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 7.39B |
| PV of terminal value | 15.09B |
| Equity value | 18.63B |
| ÷ shares → per share | $126.03 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 10.61B | 3.0% | 10.8% | 953.84M | 441.31M | 512.53M | 470.24M |
| 2 | 10.89B | 2.7% | 14.4% | 1.30B | 404.05M | 895.72M | 754.00M |
| 3 | 11.14B | 2.3% | 17.9% | 1.66B | 362.97M | 1.30B | 1.00B |
| 4 | 11.37B | 2.0% | 21.5% | 2.03B | 318.38M | 1.71B | 1.21B |
| 5 | 11.56B | 1.7% | 25.0% | 2.40B | 270.62M | 2.13B | 1.38B |
| 6 | 11.71B | 1.3% | 25.0% | 2.43B | 220.10M | 2.21B | 1.32B |
| 7 | 11.83B | 1.0% | 25.0% | 2.46B | 167.28M | 2.29B | 1.25B |
Key risks
- Leqembi uptake stays slow because of ARIA safety monitoring, infusion logistics and payer friction, while competitors like Kisunla take share
- MS franchise erosion accelerates faster than launches can replace it
- Repeated costly acquisitions and IPR&D write-offs destroy value and keep GAAP margins depressed
Catalysts
- Subcutaneous Leqembi maintenance dosing and blood-based diagnostics widen the Alzheimer's treated population
- Felzartamab and other late-stage readouts validate the HI-Bio acquisition